WHAT IS CLAIMED IS:

1. A method for killing a tumor cell, comprising contacting said tumor cell with a fusion toxin comprising the toxin domain of diphtheria toxin and a urokinase-type plasminogen activator domain.

2. The method of claim 1, wherein said tumor cell is a brain tumor cell.

3. The method of claim 2, wherein said brain tumor is selected from the group consisting of glioblastoma, meningioma, astrocytoma, medulloblastoma, ependymoma, and oligodendroglioma.

4. The method of claim 2, wherein said brain tumor is a glioblastoma.

5. The method of claim 1, wherein said tumor cell expresses the urokinase-type plasminogen activator receptor.

6. The method of claim 1, wherein contacting said tumor cell occurs *in vivo*.

7. The method of claim 1, wherein said fusion toxin comprises the translocation enhancer region of diphtheria toxin.

8. The method of claim 1, wherein said fusion toxin comprises the amino terminal 390 amino acids of diphtheria toxin.

9. The method of claim 1, wherein said urokinase-type plasminogen activator domain is capable of binding to urokinase-type plasminogen activator receptor.

10. The method of claim 9, wherein said urokinase-type plasminogen activator domain comprises the amino terminal fragment of urokinase-type plasminogen activator.

11. The method of claim 1, wherein said fusion toxin comprises the toxin domain of diphtheria toxin, the translocation enhancing region of diphtheria toxin, and the amino-terminal fragment of urokinase-type plasminogen activator.

12. A method for killing a glioblastoma tumor cell, comprising contacting said glioblastoma tumor cell with a fusion toxin comprising a urokinase-type plasminogen activator domain.

13. The method of claim 12, wherein said fusion toxin comprises a toxin domain of a toxin selected from the group consisting of diphtheria toxin, ricin, *Pseudomonas* exotoxin, colicin, anthrax toxin, tetanus toxin, botulinum neurotoxin, saporin, abrin, bryodin, pokeweed anti-viral protein, viscumin, and gelonin.

14. The method of claim 12, wherein said fusion toxin comprises the toxin domain of diphtheria toxin.

15. The method of claim 12, wherein said fusion toxin comprises an internalization domain of a toxin selected from the group consisting of diphtheria toxin, colicin, delta-Endotoxin, anthrax toxin, tetanus toxin, botulinum toxin, and *Pseudomonas* exotoxin.

16. The method of claim 12, wherein said fusion toxin comprises the translocation enhancing region of diphtheria toxin.

17. The method of claim 12, wherein said urokinase-type plasminogen activator domain is capable of binding to urokinase-type plasminogen activator receptor.

18. The method of claim 17, wherein said urokinase-type plasminogen activator domain comprises the amino-terminal fragment of urokinase-type plasminogen activator.

19. The method of claim 12, wherein said glioblastoma tumor cell expresses the urokinase-type plasminogen activator receptor.

20. The method of claim 12, wherein said fusion toxin comprises the toxin domain of diphtheria toxin, the translocation enhancing region of diphtheria toxin, and the amino-terminal fragment of the urokinase-type plasminogen activator.

21. A fusion toxin, comprising the toxin domain of diphtheria toxin and a urokinase-type plasminogen activator domain.

22. The fusion toxin of claim 21, wherein said fusion toxin further comprises the translocation enhancing region of diphtheria toxin.

23. The fusion toxin of claim 21, wherein said urokinase-type plasminogen activator domain comprises the amino-terminal fragment of urokinase-type plasminogen activator.

24. The fusion toxin of claim 21, wherein said toxin comprises the toxin domain of diphtheria toxin, the translocation enhancing region of diphtheria toxin, and the amino-terminal fragment of urokinase-type plasminogen activator.

25. A pharmaceutical composition, comprising the fusion toxin of claim 21.

26. An article of manufacture, comprising the pharmaceutical composition of claim 21.

27. A nucleic acid comprising a sequence that encodes the fusion toxin of claim 21.

28. A vector comprising the nucleic acid sequence of claim 27 operably linked to expression control sequences.

29. A host cell comprising the vector of claim 28 and expressing a fusion toxin, said fusion toxin comprising the toxin domain of diphtheria toxin and a urokinase-type plasminogen activator domain.